. 2025 Jul 8;12:1571395. doi: 10.3389/fcvm.2025.1571395

Table 3.

Cox regression model for the highest Lp(a) category (≥90 mg/dl) vs. the lowest category (<30 mg/dl), stratified for length of follow-up (increasing from 0 to 12 months, plus 6 months each), in selected subgroups.

Follow-up (months)	Dyslipidemia				Dyslipidemia without statin treatment				History of multiple CVD events at baseline
	Events N		HR (95% CI)^a	p-value	Events N		HR (95% CI)^a		Events N		HR (95% CI)^a	p-value
	<30 mg/dl, N = 491	≥90 mg/dl, N = 39	HR (95% CI)^a	p-value	<30 mg/dl, N = 122	≥90 mg/dl, N = 11	HR (95% CI)^a		<30 mg/dl, N = 253	≥90 mg/dl, N = 11	HR (95% CI)^a	p-value
Overall	127	11	1.34 (0.72–2.50)	0.36	23	6	4.93 (1.77–13.7)	0.002	82	6	3.95 (1.60–9.73)	0.003
0–12	15	4	4.32 (1.37–13.6)	0.012	5	2	7.41 (1.14–48.1)	0.036	9	3	26.3 (5.66–123)	<0.0001
0–18	22	6	4.56 (1.78–11.7)	0.002	5	3	11.0 (1.98–61.1)	0.006	15	5	25.6 (7.83–83.8)	<0.0001
0–24	34	8	4.66 (2.09–10.4)	0.0002	10	3	7.75 (1.73–34.7)	0.007	25	6	22.1 (7.89–62.0)	<0.0001
0–30	39	8	3.86 (1.76–8.50)	0.001	12	3	5.90 (1.38–25.1)	0.016	27	6	21.6 (7.79–60.1)	<0.0001
0–36	46	8	3.08 (1.42–6.67)	0.004	12	3	5.49 (1.29–23.3)	0.021	30	6	18.5 (6.78–50.3)	<0.0001
0–42	59	9	2.54 (1.24–5.21)	0.011	13	4	6.91 (1.85–25.8)	0.004	37	6	12.9 (4.92–34.0)	<0.0001
0–48	64	9	2.31 (1.14–4.71)	0.021	14	4	5.98 (1.67–21.4)	0.006	41	6	12.4 (4.74–32.3)	<0.0001
0–54	73	9	1.98 (0.98–4.00)	0.06	15	4	5.56 (1.58–19.6)	0.008	45	6	10.1 (3.93–26.1)	<0.0001
0–60	79	9	1.82 (0.90–3.67)	0.09	15	4	5.56 (1.58–19.6)	0.008	47	6	8.84 (3.45–22.6)	<0.0001

^{^a}

Age, sex, body mass index, Mediterranean Diet Score, food intake, glucose, total cholesterol, and (except for subgroup without subjects treated with) statin treatment were covariates; in bold p < 0.05.